Options Traders Eye Rumored Takeover Target Pharmacyclics, Inc. (PCYC)

Pharmacyclics, Inc. (PCYC) hit an all-time high earlier on reports it is exploring a sale

Feb 25, 2015 at 2:26 PM
facebook X logo linkedin


After trading modestly higher for most of the morning, Pharmacyclics, Inc. (NASDAQ:PCYC) has jumped 17.7% to $221.60 -- and earlier hit an all-time peak of $231.09 -- amid reports the drugmaker could be exploring a possible sale. Johnson & Johnson (NYSE:JNJ) and Novartis AG (ADR) (NYSE:NVS) are rumored to be among the potential suitors, the former of which just received a big payday to end a multi-year lawsuit with Boston Scientific Corporation (NYSE:BSX). The news has sparked a rush of activity in th equity's options pits, with total volume running at seven times what's typically seen at this point in the day.

Drilling down, eight of PCYC's 10 most active options reside in the March series, with the 200-strike call garnering notable attention. It appears as if a number of new positions are being purchased here, meaning speculators are gambling on PCYC to extend its lead north of the round-number $200 mark through the close on Friday, March 20, when front-month options expire. Delta on the call is docked at 0.79, suggesting a roughly 4-in-5 chance of an in-the-money finish.

From a wider sentiment perspective, it's been puts, not calls, that options traders have preferred. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), PCYC's 10-day put/call volume ratio of 1.21 ranks in the 92nd annual percentile. Simply stated, puts have been bought to open over calls with more rapidity just 8% of the time within the past year.

Even more telling of this put-skewed bias is the security's Schaeffer's put/call open interest ratio (SOIR) of 1.20. Not only does this show that put open interest outweighs call open interest among options set to expire in three months or less, but it rests at an annual high. In other words, speculative traders are more put-heavy now toward Pharmacyclics, Inc. (NASDAQ:PCYC) than they've been at any other point over the last 12 months.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI